Arch Therapeutics Inc (ARTH)

[Polyphemus]

$30/share? Two things would have to happen. 1st - ARTH would have to have a blockbuster product - more than $100M in annual revenues in the 2nd or 3rd year of commercialization & very profitable. 2nd - ARTH would need a reverse split of about 1:12. The probability of the first condition can now be competently estimated by the factual history. 17 months of US regulatory approval & no visible demand. This is not like a lot of other small companies that might stall or fail; TN & ARTH are special.